The effects of Filgrastimin on Complications of patients with cerebral hemorrhage ?due to head trauma ?

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017020120258N30

Enrollment

Registered

2017-02-14

Start date

2016-06-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral hemorrhage ?due to head trauma. Intracerebral haemorrhage in hemisphere, cortical

Interventions

Intervention 1: Intervention group: We will inject 150 micro gram Filgrastimin subcutaneous in 4 day in ?intervention group (34 patients). ?. Intervention 2: Control group: We will inject normal salin

Treatment - Drugs

Intervention group: We will inject 150 micro gram Filgrastimin subcutaneous in 4 day in ?intervention group (34 patients). ?

Control group: We will inject normal saline in control group ( 34 patients). ?

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18 years and more; patients with cerebral hemorrhage due to head trauma; level of consciousness between 9 -13 Exclusion criteria: alcohol consumption and addiction; allergy for drug; history of hypertension and diabetes and embolism and deep vein thrombosis; patient died 72 hours after admission

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: Before and in and after treatment. Method of measurement: Barometer.;Hemoglobin. Timepoint: Before and in and after treatment. Method of measurement: Blood test.;Electrolytes. Timepoint: Before and in and after treatment. Method of measurement: Blood test.;Hematocrit. Timepoint: Before and in and after treatment. Method of measurement: Blood test.;Paralyzed limb strength ?. Timepoint: before and after treatment. Method of measurement: Physical examination.;Deep vein thrombosis. Timepoint: before and after treatment. Method of measurement: CT venography.;Number of hospitalization days ?. Timepoint: After treatment. Method of measurement: Observation.;Mortality. Timepoint: After treatment. Method of measurement: Observation.	—

Measure

Time frame

Blood pressure. Timepoint: Before and in and after treatment. Method of measurement: Barometer.;Hemoglobin. Timepoint: Before and in and after treatment. Method of measurement: Blood test.;Electrolytes. Timepoint: Before and in and after treatment. Method of measurement: Blood test.;Hematocrit. Timepoint: Before and in and after treatment. Method of measurement: Blood test.;Paralyzed limb strength ?. Timepoint: before and after treatment. Method of measurement: Physical examination.;Deep vein thrombosis. Timepoint: before and after treatment. Method of measurement: CT venography.;Number of hospitalization days ?. Timepoint: After treatment. Method of measurement: Observation.;Mortality. Timepoint: After treatment. Method of measurement: Observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Morteza Gharibi

Arak University of Medical Sciences

fa.farokhi@gmail.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026